Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker CRVS, has announced that it will participate in the Jefferies Global Health Conference in New York from June 5-7, 2024. The company's CEO, Richard A. Miller, and Chief Business Officer, Jeffrey Arcara, will present a corporate overview and conduct one-on-one meetings with investors. The presentation is scheduled for June 5 at 3:00 pm ET and will be webcast live, with the recording available for 90 days on the company's investor relations webpage.
- Corvus Pharmaceuticals' participation in a prestigious event like the Jefferies Global Health Conference could enhance its visibility among investors.
- The availability of a live webcast and a 90-day recording provides extended accessibility for potential investors, increasing transparency.
- No new clinical data or financial results are being presented, which might not meet the expectations of investors looking for updates.
BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Global Health Conference, which is being held in New York from June 5-7, 2024. The Company’s presentation will be on Wednesday, June 5 at 3:00 pm ET.
A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
![](https://ml.globenewswire.com/media/ZDIwODRkMDgtNTgzMi00NzZmLTkxYTctZDNhZTQ1OGNlOTY2LTEwMzc1NjU=/tiny/Corvus-Pharmaceuticals-Inc-.png)
FAQ
When and where will Corvus Pharmaceuticals present at the Jefferies Global Health Conference?
Who will represent Corvus Pharmaceuticals at the Jefferies Global Health Conference?
Where can investors watch the Corvus Pharmaceuticals presentation at the Jefferies Global Health Conference?